PAS
RCUS icon

Point72 Asia (Singapore)’s Arcus Biosciences RCUS Stock Holding History

Point72 Asia (Singapore)’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,396
Closed -$81.6K – 1198
2025
Q1 		$81.6K Sell
10,396
-4,787
-32% -$55.5K 0.02% 459
2024
Q4 		$226K Sell
15,183
-5,164
-25% -$84.3K 0.06% 227
2024
Q3 		$311K Sell
20,347
-6,330
-24% -$99.8K 0.06% 268
2024
Q2 		$406K Buy
+26,677
New +$431K 0.08% 182

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Point72 Asia (Singapore)'s RCUS Position: Q2 2025 in Review

Point72 Asia (Singapore) sold out of Arcus Biosciences (RCUS) in Q2 2025, closing a stake of 10,396 shares — an estimated $81.6K sold.

Point72 Asia (Singapore) first reported a position in RCUS in Q2 2024 and held it in 4 quarters. The position peaked at $406K in Q2 2024. 185 funds tracked by Wall St. Rank hold RCUS as of Q2 2025.

  • Point72 Asia (Singapore) reported no remaining Arcus Biosciences position as of Q2 2025 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 10,396 Arcus Biosciences shares in Q2 2025, an estimated $81.6K.
  • Point72 Asia (Singapore) first reported a position in Arcus Biosciences in Q2 2024 and held it in 4 quarters.
  • Point72 Asia (Singapore)'s Arcus Biosciences position peaked at $406K in Q2 2024.
  • 185 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q2 2025, filed 14 Aug 2025.